FGEN FibroGen Inc

18.57
-0.24  -1%
Previous Close 18.81
Open 18.74
52 Week Low 18.12
52 Week High 57.2088
Market Cap $1,700,277,891
Shares 91,560,468
Float 80,122,555
Enterprise Value $1,074,289,403
Volume 4,082,358
Av. Daily Volume 1,608,659
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Roxadustat
Anaemia in Chronic Kidney Disease
PDUFA
PDUFA
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Roxadustat
Chemotherapy-induced anemia (CIA)
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Roxadustat
Myelodysplastic syndromes (MDS)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Pamrevlumab - LELANTOS
Duchenne muscular dystrophy
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Pamrevlumab (LAPIS)
Pancreatic cancer
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Pamrevlumab
COVID-19
Phase 2
Phase 2
Phase 2 commencement of enrolment announced June 23, 2020.
Pamrevlumab - LELANTOS-2
Duchenne Muscular Dystrophy
Phase 3
Phase 3
Phase 3 second trial initiation announced March 16, 2021.
Pamrevlumab (FG-3019) - ZEPHYRUS
Idiopathic pulmonary fibrosis
Phase 3
Phase 3
Phase 3 trial initiation announced July 22, 2019. Second Phase 3 trial initiation announced December 22, 2020.
Pamrevlumab - Borea
COVID-19
Phase 2/3
Phase 2/3
Phase 2/3 commencement of enrolment in Italy trial announced June 8, 2020.

Latest News

  1. San Francisco, California--(Newsfile Corp. - April 8, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law claims against FibroGen Inc. (NASDAQ:FGEN) ("FibroGen" or the "Company"). FibroGen is a biopharmaceutical company developing roxadustat, a treatment of anemia in chronic kidney disease ("CKD").

    On November 8, 2019, the Company issued a press release announcing, "Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease". In response to this news, shares of FibroGen traded up $3.65 per share to close at $41.62 on November 8, 2019 from a close of $37.97 on November 7, 2019 (up approximately 10%), on heavy volume.

    On April 6…

    San Francisco, California--(Newsfile Corp. - April 8, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law claims against FibroGen Inc. (NASDAQ:FGEN) ("FibroGen" or the "Company"). FibroGen is a biopharmaceutical company developing roxadustat, a treatment of anemia in chronic kidney disease ("CKD").

    On November 8, 2019, the Company issued a press release announcing, "Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease". In response to this news, shares of FibroGen traded up $3.65 per share to close at $41.62 on November 8, 2019 from a close of $37.97 on November 7, 2019 (up approximately 10%), on heavy volume.

    On April 6, 2021, after the market closed, the Company issued a press release to "provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of [CKD]". The Company stated that it "became aware that the primary cardiovascular safety analyses included post-hoc changes to the stratification factors".

    In response to this news, shares of FibroGen closed on April 7, 2021 at $19.74 per share down $14.90 per share from its close of $34.64 on April 6, 2021 (a decline of approximately 43%).

    If you purchased FibroGen securities between November 7, 2019 and April 6, 2021, inclusive, and would like more information regarding this investigation, or if you wish simply to share information about the investigation, please visit: http://www.bermantabacco.com/case/fibrogen-inc/.

    Berman Tabacco is a national law firm representing institutions and individuals in lawsuits, seeking to recoup losses caused by corporate and board misconduct and violations of the securities and antitrust laws. The firm has offices in San Francisco, California and Boston, Massachusetts.

    This notice may constitute attorney advertising.

    Contact:
    Jeffrey Rocha, Esq.
    (800) 516-9926
    Email:

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/79834

    View Full Article Hide Full Article
  2. NEW YORK, April 7, 2021 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of FibroGen, Inc. (NASDAQ:FGEN) common stock.

    FibroGen is a biopharmaceutical company. One of its lead drugs is roxadustat, which promotes red blood cell production. Roxadustat is currently approved for sale in China, Japan and Chile for treatment of anemia for patients with chronic kidney disease. FibroGen submitted a New Drug Application (NDA) to the FDA for roxadustat in December 2019. On March 1, 2021, the FDA informed FibroGen that the Cardiovascular and Renal Drugs Advisory Committee would hold an advisory committee meeting to review the NDA for roxadustat. That news was unexpected and caused FibroGen's stock…

    NEW YORK, April 7, 2021 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of FibroGen, Inc. (NASDAQ:FGEN) common stock.

    FibroGen is a biopharmaceutical company. One of its lead drugs is roxadustat, which promotes red blood cell production. Roxadustat is currently approved for sale in China, Japan and Chile for treatment of anemia for patients with chronic kidney disease. FibroGen submitted a New Drug Application (NDA) to the FDA for roxadustat in December 2019. On March 1, 2021, the FDA informed FibroGen that the Cardiovascular and Renal Drugs Advisory Committee would hold an advisory committee meeting to review the NDA for roxadustat. That news was unexpected and caused FibroGen's stock price to fall almost 25% to $38.07 per share.

    After the market closed on April 6, 2021, FibroGen announced that while it was preparing for the Advisory Committee meeting, it became "aware that the primary cardiovascular safety analyses included post-hoc changes to the stratification factors" and that it  "promptly decided to clarify this issue with the FDA."  Adam Feuerstein, the biotech reporter at STAT+, said "Fibrogen acknowledged Tuesday that the company has been touting false heart-safety data for its experimental anemia pill for at least two years — a shocking revelation that raises even more questions about the drug's approvability."

    In early morning trading on April 7, 2021, FibroGen's stock price fell $12.42 per share to trade at $22.22.

    For more information, FibroGen investors with trading losses of over $50,000 should contact Joshua Ruthizer at (212) 451-9668 or at jruthizermailto:@wolfpopper.com.

    Wolf Popper has successfully recovered billions of dollars for defrauded investors.  Wolf Popper's reputation and expertise have been repeatedly recognized by the courts, which have appointed the firm to major positions in securities litigation.  For more information about Wolf Popper, please visit the Firm's website at www.wolfpopper.com.

    Attorney Advertising: Prior Results Do Not Guarantee A Similar Outcome.

    Wolf Popper LLP

    Joshua W. Ruthizer

    845 Third Avenue

    New York, NY 10022

    Tel.: (212) 451-9668

    Email:

    Cision View original content:http://www.prnewswire.com/news-releases/wolf-popper-llp-announces-investigation-on-behalf-of-purchasers-of-fibrogen-inc-fgen-common-stock-301264381.html

    SOURCE Wolf Popper LLP

    View Full Article Hide Full Article
  3. San Francisco, California--(Newsfile Corp. - April 7, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law claims against FibroGen Inc. ("FibroGen" or the "Company") (NASDAQ:FGEN). FibroGen is a San Francisco-based biopharmaceutical company developing Roxadustat, a treatment of anemia in chronic kidney disease ("CKD").

    On November 8, 2019, the Company issued a press release announcing, "Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease." In response to this news, shares of FibroGen traded up $3.65 per share to close at $41.62 on November 8, 2019 from a close of $37.97 on November 7, 2019 (up approximately 10%), on heavy volume…

    San Francisco, California--(Newsfile Corp. - April 7, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law claims against FibroGen Inc. ("FibroGen" or the "Company") (NASDAQ:FGEN). FibroGen is a San Francisco-based biopharmaceutical company developing Roxadustat, a treatment of anemia in chronic kidney disease ("CKD").

    On November 8, 2019, the Company issued a press release announcing, "Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease." In response to this news, shares of FibroGen traded up $3.65 per share to close at $41.62 on November 8, 2019 from a close of $37.97 on November 7, 2019 (up approximately 10%), on heavy volume.

    On April 6, 2021, after the market closed, the Company issued a press release to "provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of [CKD]." The Company stated that it "became aware that the primary cardiovascular safety analyses included post-hoc changes to the stratification factors."

    In response to this news, shares of FibroGen opened on April 7, 2021 at $23.87 per share down $10.77 per share from its close of $34.64 on April 6, 2021 (a decline of approximately 31%).

    If you have FibroGen securities and would like more information regarding this investigation, or if you wish simply to share information about the investigation, please visit: http://www.bermantabacco.com/case/fibrogen-inc/.

    Berman Tabacco is a national law firm representing institutions and individuals in lawsuits, seeking to recoup losses caused by corporate and board misconduct and violations of the securities and antitrust laws. The firm has offices in San Francisco, California and Boston, Massachusetts.

    This notice may constitute attorney advertising.

    Contact:
    Jeffrey Rocha, Esq.
    (800) 516-9926
    Email:

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/79703

    View Full Article Hide Full Article
  4. SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced that the U.S. Food and Drug Administration (FDA) has informed the Company late today it has tentatively scheduled a Cardiovascular and Renal Drug Advisory Committee (CRDAC) on July 15, 2021 to review the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis-dependent patients.

    The NDA submission was supported by positive results from a global Phase 3 program encompassing more than 8,000 patients. Roxadustat is approved and launched in China and Japan for the treatment of anemia of CKD in patients on dialysis and not on dialysis.

    About Cardiovascular and Renal

    SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced that the U.S. Food and Drug Administration (FDA) has informed the Company late today it has tentatively scheduled a Cardiovascular and Renal Drug Advisory Committee (CRDAC) on July 15, 2021 to review the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis-dependent patients.

    The NDA submission was supported by positive results from a global Phase 3 program encompassing more than 8,000 patients. Roxadustat is approved and launched in China and Japan for the treatment of anemia of CKD in patients on dialysis and not on dialysis.

    About Cardiovascular and Renal Drugs Advisory Committee

    The Cardiovascular and Renal Drugs Advisory Committee (CRDAC) reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational drug products for use in the treatment of cardiovascular and renal disorders, and makes appropriate recommendations to the Commissioner of Food and Drugs. Although the FDA will consider the recommendation of the panel, the final decision regarding the approval of a product is made solely by the FDA.

    About Anemia of CKD

    Chronic kidney disease (CKD) is generally a progressive disease characterized by gradual loss of kidney function that may eventually lead to kidney failure or end stage renal disease, requiring dialysis or kidney transplant. CKD is estimated to occur in approximately 10-12% of adults worldwide and is predicted to become the fifth most common cause of premature death globally by 2040.

    Anemia, a serious medical condition in which patients have insufficient red blood cells and low levels of hemoglobin, is a common early complication of CKD, affecting approximately 20% of CKD patients. Anemia of CKD is associated with an increased risk of hospitalization, cardiovascular complications, and death, and can also cause significant fatigue, cognitive dysfunction and reduced quality of life. Blood transfusions are used for treating severe anemia, however, they may reduce a patient's opportunity for kidney transplant and can increase the risk of infection and/or complications such as heart failure and allergic reactions.

    About Roxadustat

    Roxadustat, an oral medicine, is the first in a new class of medicines, HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin; improved iron absorption and mobilization; and downregulation of hepcidin. Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).

    Roxadustat is approved in China, Japan, and Chile for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD). In Europe, the Marketing Authorization Application for roxadustat for the treatment of anemia of CKD in patients both on dialysis and not on dialysis was filed by our partner Astellas and accepted by the European Medicines Agency for review on May 2020. Several other licensing applications for roxadustat have been submitted by Astellas and AstraZeneca to regulatory authorities across the globe, and are currently in review.

    Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in territories including Japan, Europe, Turkey, Russia and the Commonwealth of Independent States, the Middle East, and South Africa. FibroGen and AstraZeneca are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in the U.S., China, other markets in the Americas, in Australia/New Zealand, and Southeast Asia.

    About FibroGen

    FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and idiopathic pulmonary fibrosis (IPF). For more information, please visit www.fibrogen.com.

    Forward Looking Statements

    This release contains forward-looking statements regarding the Company's prospects, including statements regarding the safety and efficacy profile of our product candidates and regulatory results, strategy and interactions, including those of our partners. Forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "will", "should," "on track," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the Securities and Exchange Commission (SEC), and the risk factors set forth therein, including without limitation, risks related to obtaining regulatory approval and the planned FDA Advisory Committee meeting. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts:

    FibroGen, Inc.

    Investors:

    Michael Tung, M.D.

    Corporate Strategy / Investor Relations

    1.415.978.1434

    Media:

    Jennifer Harrington

    1.610.574.9196

     



    Primary Logo

    View Full Article Hide Full Article
  5. Company Continues to be Confident in the Benefit / Risk Profile of Roxadustat

    Company to Host Investor Call Today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time)

    SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (the "Company") today provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease ("CKD").

    "As members of senior management were preparing for the upcoming FDA Advisory Committee meeting, we became aware that the primary cardiovascular safety analyses included post-hoc changes to the stratification factors," said Enrique Conterno, Chief Executive Officer, FibroGen. "While…

    Company Continues to be Confident in the Benefit / Risk Profile of Roxadustat

    Company to Host Investor Call Today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time)

    SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (the "Company") today provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease ("CKD").

    "As members of senior management were preparing for the upcoming FDA Advisory Committee meeting, we became aware that the primary cardiovascular safety analyses included post-hoc changes to the stratification factors," said Enrique Conterno, Chief Executive Officer, FibroGen. "While all of the analyses set forth below, including the differences in the stratification factors, were included in the NDA, we promptly decided to clarify this issue with the FDA and communicate with the scientific and investment communities."

    Mr. Conterno continued, "It is important to emphasize that this does not impact our conclusion regarding the comparability, with respect to cardiovascular safety, of roxadustat to epoetin-alfa in dialysis-dependent (DD) patients and to placebo in non-dialysis dependent (NDD) patients. We continue to have confidence in roxadustat's benefit risk profile."

    FibroGen continues to prepare for the FDA Advisory Committee meeting and will work closely with the FDA to bring this important new treatment to patients living with anemia of CKD.

    There is no change in the underlying roxadustat data, or to the efficacy analyses from the Phase 3 program. The Company has begun a comprehensive internal review to ensure such issues do not occur in the future.

    Pooled Cardiovascular Safety Data

    As previously disclosed, the Company agreed with the FDA in the pre-NDA meeting that the primary analysis in non-dialysis would be ITT (intention to treat with long-term follow up) and in dialysis would be OT-7 (on-treatment plus 7 days). MACE, a composite endpoint of all-cause mortality, stroke, and myocardial infarction, was the primary safety endpoint agreed on with the FDA.

    The table below describes the cardiovascular safety results using the post-hoc stratification factors reported at the American Society of Nephrology conference in November 2019, as well as the analyses with the pre-specified stratification factors which have not been previously publicly reported.

      Analyses with post-hoc stratification factorsAnalyses with pre-specified stratification factors
      HR (95% Confidence Interval)HR (95% Confidence Interval)
    Non Dialysis (OLYMPUS, ANDES, ALPS N=4,270); ITT 
    MACE1.08 (0.94, 1.24)1.10 (0.96, 1.27)
    MACE+1.04 (0.91, 1.18)1.07 (0.94, 1.21)
    ACM1.06 (0.91, 1.23)1.08 (0.93, 1.26)
    Dialysis  Dependent (HIMALAYAS, SIERRAS, ROCKIES N=3,880); OT-7
    MACE0.96 (0.82, 1.13)1.02 (0.88, 1.20)
    MACE+0.86 (0.74, 0.98)0.91 (0.80, 1.05)
    ACM0.96 (0.79, 1.17)1.02 (0.84, 1.23)
     Incident Dialysis (N=1,526); OT-7 
     MACE0.70 (0.51, 0.96)0.82 (0.60, 1.11)
     MACE+0.66 (0.50, 0.89)0.78 (0.59, 1.02)
     ACM0.76 (0.52, 1.11)0.82 (0.57, 1.18)
      
    ITT: intention to treat with long-term follow up
    OT-7: on-treatment plus 7 days
    Major Adverse Cardiovascular Event (MACE): a composite endpoint of all-cause mortality, stroke, and myocardial infarction.
    (MACE+): in addition to the components in MACE, includes hospitalization due to heart failure or unstable angina.
    (ACM): all-cause mortality.

    As reflected in the table, the analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals. For MACE+ in dialysis and for MACE and MACE+ in incident dialysis, the 95% confidence intervals include 1.0. While these hazard ratios remain below 1.0, based on these analyses we cannot conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa.  

    These analyses do not change the Company's assessment that roxadustat is comparable to placebo in non-dialysis dependent patients and to epoetin-alfa in dialysis dependent patients using MACE to measure cardiovascular safety.

    As previously announced, roxadustat has been launched in China and Japan for the treatment of anemia of CKD in both NDD and DD adult patients. These approvals were based on different studies conducted in the relevant geographies. In Europe, the Marketing Authorization Application for roxadustat for the treatment of anemia of CKD in patients both on dialysis and not on dialysis was filed by FibroGen's partner Astellas and accepted by the European Medicines Agency for review in May 2020.

    Conference Call and Webcast Details

    FibroGen will host a conference call and webcast today, April 6, 2021, at 5:00 pm Eastern Time (2:00 p.m. Pacific Time) to discuss this matter. Interested parties may access a live audio webcast of the conference call via the FibroGen website at https://fibrogen.gcs-web.com/events-and-presentations/events. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software.

    Dial-In Information

    Live (U.S./Canada): (877) 658-9081

    Live (International): (602) 563-8732

    Confirmation number: 5297733

    A replay of the webcast and investor presentation will be available shortly after the call for a period of 30 days. To access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international), and use passcode 5297733.

    About Anemia of CKD

    Chronic kidney disease (CKD) is generally a progressive disease characterized by gradual loss of kidney function that may eventually lead to kidney failure or end stage renal disease, requiring dialysis or kidney transplant. CKD is estimated to occur in approximately 10-12% of adults worldwide and is predicted to become the fifth most common cause of premature death globally by 2040.

    Anemia, a serious medical condition in which patients have insufficient red blood cells and low levels of hemoglobin, is a common early complication of CKD, affecting approximately 20% of CKD patients. Anemia of CKD is associated with an increased risk of hospitalization, cardiovascular complications, and death, and can also cause significant fatigue, cognitive dysfunction and reduced quality of life. Blood transfusions are used for treating severe anemia, however, they may reduce a patient's opportunity for kidney transplant and can increase the risk of infection and/or complications such as heart failure and allergic reactions.

    About Roxadustat

    Roxadustat, an oral medicine, is the first in a new class of medicines, HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin; improved iron absorption and mobilization; and downregulation of hepcidin. Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).

    Roxadustat is approved in China, Japan, and Chile for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD). In Europe, the Marketing Authorization Application for roxadustat for the treatment of anemia of CKD in patients both on dialysis and not on dialysis was filed by our partner Astellas and accepted by the European Medicines Agency for review on May 2020. Several other licensing applications for roxadustat have been submitted by Astellas and AstraZeneca to regulatory authorities across the globe, and are currently in review.

    Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in territories including Japan, Europe, Turkey, Russia and the Commonwealth of Independent States, the Middle East, and South Africa. FibroGen and AstraZeneca are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in the U.S., China, other markets in the Americas, in Australia/New Zealand, and Southeast Asia.

    About FibroGen

    FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and idiopathic pulmonary fibrosis (IPF). For more information, please visit www.fibrogen.com.

    Forward Looking Statements

    This release contains forward-looking statements regarding the Company's prospects, including statements regarding the safety and efficacy profile of our product candidates and regulatory results, strategy and interactions, including those of our partners. Forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "will", "should," "on track," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the Securities and Exchange Commission (SEC), and the risk factors set forth therein, including without limitation, risks related to obtaining regulatory approval and the planned FDA Advisory Committee meeting. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts:

    FibroGen, Inc.

    Investors:

    Michael Tung, M.D.

    Corporate Strategy / Investor Relations

    1.415.978.1434

    Media:

    Jennifer Harrington

    +1.610.574.9196

     



    Primary Logo

    View Full Article Hide Full Article
View All FibroGen Inc News